Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes

Trial Profile

A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2018

At a glance

  • Drugs Efpeglenatide (Primary) ; Liraglutide
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms EXCEED
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 17 Oct 2018 Patients were not recruited from Netherlands.
    • 05 Oct 2018 Results assessing the effects of efpeglenatide on total cholesterol, LDL-cholesterol (LDL-C), HDL-C, VLDL-C, and triglycerides (TG) in patients from 2 phase 2 trials (EXCEED 203 and BALANCE 205) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top